Search results
Results from the WOW.Com Content Network
(Reuters) -Gilead Sciences said on Thursday a late-stage study showed its long-acting injectable drug was more effective in preventing HIV infection in women compared to its existing daily pill ...
The FDA has approved ViiV Healthcare's Apretude, the first and only long-acting injectable pre-exposure prophylaxis (PrEP) option, to reduce the risk of sexually acquired HIV-1.
The pharma giant has already secured approval for the injectable drug in treating highly drug-resistant HIV. Lenacapavir’s current list price for use as HIV treatment is $3,450 per month.
U.S. FDA approves Gilead's long-acting HIV drug Sunlenca December 22, 2022 at 11:26 AM FILE PHOTO: The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California
Dr. Marc Siegel, senior medical analyst for Fox News, practices at NYU Langone Health, which performed 576 organ transplants in 2023. "I don't have a problem with HIV organs being used, because we ...
Emtricitabine/tenofovir is also used for HIV post-exposure prophylaxis. People who start taking emtricitabine/tenofovir see HIV reduction benefits up to 72 hours after starting, but the medicine must be taken for thirty days after a high-risk sexual event to ensure HIV transmission levels are optimally reduced. [21] [22]
Etravirine (ETR, [3]), sold under the brand name Intelence is an antiretroviral medication used for the treatment of HIV. [1] Etravirine is a human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI). [1] Unlike agents in the class, resistance to other NNRTIs does not seem to confer resistance to ...
Fosamprenavir (FPV), sold under the brand names Lexiva and Telzir, is a medication used to treat HIV/AIDS. [3] [4] It is a prodrug of the protease inhibitor and antiretroviral drug amprenavir. [5] It is marketed by ViiV Healthcare as the calcium salt. [3] [4]